TrianglePUBLICATIONS · 37559050
REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Mol Cancer
- Publication date
- 2023 Aug 9
- First author
- Martin-Broto J
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Martin-Broto J
- type
- Author
- name
- Valverde C
- type
- Author
- name
- Hindi N
- type
- Author
- name
- Vincenzi B
- type
- Author
- name
- Martinez-Trufero J
- type
- Author
- name
- Grignani G
- type
- Author
- name
- Italiano A
- type
- Author
- name
- Lavernia J
- type
- Author
- name
- Vallejo A
- type
- Author
- name
- Tos PD
- type
- Author
- name
- Le Loarer F
- type
- Author
- name
- Gonzalez-Campora R
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Martin-Broto J
- type
- Author
- name
- Valverde C
- type
- Author
- name
- Hindi N
- type
- Author
- name
- Vincenzi B
- type
- Author
- name
- Martinez-Trufero J
- type
- Author
- name
- Grignani G
- type
- Author
- name
- Italiano A
- type
- Author
- name
- Lavernia J
- type
- Author
- name
- Vallejo A
- type
- Author
- name
- Tos PD
- type
- Author
- name
- Le Loarer F
- type
- Author
- name
- Gonzalez-Campora R
- type
- Author
- bibliography ids
- nci-bib-94bca58160fcf14085e4a2b4
- book metadata
- content sha256
- 66ff1ed641de5a84b57d4507a7809d4df035117aa67fe2fd3a7551f599209229
- document type
- citation
- dois
- 10.1186/s12943-023-01832-9
- electronic publication date
- display
- 2023 Aug 9
- precision
- day
- year
- 2023
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:37559050
- immutable id
- pubmed:37559050@66ff1ed641de5a84b57d4507a7809d4df035117aa67fe2fd3a7551f599209229
- journal
- abbreviation
- Mol Cancer
- issn electronic
- 1476-4598
- issn print
- Source null
- issue
- 1
- name
- Molecular cancer
- nlm unique id
- 101147698
- pages
- 127
- volume
- 22
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 37559050
- provenance
- batch id
- 5329a5d0877ee70ecd11
- provider
- NCBI PubMed ESummary
- record sha256
- e924232aa74b2329f00ea55b8cdf67bdf27a9afd981f303a14bd62f1cee6673a
- response sha256
- bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
- retrieved at
- 2026-09-09T23:48:15.763286+00:00
- publication date
- display
- 2023 Aug 9
- precision
- day
- year
- 2023
- publication types
- Clinical Trial, Phase II
- Letter
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial.
Preserved source evidence · Not medical advice